255 related articles for article (PubMed ID: 8636744)
1. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
[TBL] [Abstract][Full Text] [Related]
2. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W;
Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131
[TBL] [Abstract][Full Text] [Related]
4. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
Sikic BI; Scudder SA; Ballon SC; Soriero OM; Christman JE; Suey L; Ehsan MN; Brandt AE; Evans TL
Semin Oncol; 1986 Dec; 13(4 Suppl 4):26-32. PubMed ID: 3099393
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
Pautier P; Vergote I; Joly F; Melichar B; Kutarska E; Hall G; Lisyanskaya A; Reed N; Oaknin A; Ostapenko V; Zvirbule Z; Chetaille E; Geniaux A; Shoaib M; Green JA
Int J Gynecol Cancer; 2017 Feb; 27(2):258-266. PubMed ID: 27870712
[TBL] [Abstract][Full Text] [Related]
6. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association.
Muss HB; Case LD; Capizzi RL; Cooper MR; Cruz J; Jackson D; Richards F; Powell BL; Spurr CL; White D
J Clin Oncol; 1990 Nov; 8(11):1797-805. PubMed ID: 2230868
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
[TBL] [Abstract][Full Text] [Related]
9. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities.
Aisner J; Tchekmedyian NS; Moody M; Tait N
Semin Hematol; 1987 Apr; 24(2 Suppl 1):48-55. PubMed ID: 3589708
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study.
Pinelli DM; Fiorica JV; Roberts WS; Hoffman MS; Nicosia SV; Cavanagh D
Gynecol Oncol; 1996 Mar; 60(3):462-7. PubMed ID: 8774658
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Thigpen T; Brady MF; Homesley HD; Soper JT; Bell J
J Clin Oncol; 2001 Jan; 19(2):364-7. PubMed ID: 11208827
[TBL] [Abstract][Full Text] [Related]
12. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
15. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Fleming GF; Filiaci VL; Marzullo B; Zaino RJ; Davidson SA; Pearl M; Makker V; Burke JJ; Zweizig SL; Van Le L; Hanjani P; Downey G; Walker JL; Reyes HD; Leslie KK
Gynecol Oncol; 2014 Mar; 132(3):585-92. PubMed ID: 24456823
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
19. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
20. The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma.
Geisler HE
Semin Oncol; 1985 Mar; 12(1 Suppl 1):20-2. PubMed ID: 3975647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
